Related Experiment Videos
Endothelin: new discoveries and rapid progress in the clinic
D J Webb1, J C Monge, T J Rabelink
1Department of Medicine, University of Edinburgh, Western General Hospital, UK.
Trends in Pharmacological Sciences
|March 24, 1998
Summary
Endothelin (ET) antagonists show promise for cardiovascular diseases like heart failure and hypertension. While ETA blockade is beneficial, ETB receptor roles in vasodilation and natriuresis suggest potential protective effects, warranting further research into selective ETA antagonists.
Area of Science:
- Cardiovascular Physiology
- Endocrinology
- Pharmacology
Background:
- Endothelin (ET) system involvement in embryonic development, growth, and cardiovascular homeostasis.
- ET-1's critical pathophysiological role in decompensated vascular homeostasis, particularly in congestive heart failure (CHF).
- Emerging evidence for ET antagonists in hypertension, stroke, subarachnoid hemorrhage, and renal failure.
Framework:
- Development of selective endothelin receptor antagonists (ETA and ETB).
- Exploration of endothelin-converting enzyme-1 (ECE-1) inhibition as an alternative therapeutic strategy.
- Investigating the contrasting roles of ETA and ETB receptor blockade in cardiovascular and renal diseases.
Implementation:
- Large-scale morbidity and mortality studies for ET antagonists in CHF are justified.
- Clinical trials are anticipated for various cardiovascular and renal indications.
- Research is expanding into non-cardiovascular fields, including cancer treatment.
Implications:
- Consensus supports ETA blockade for cardiovascular and renal diseases.
- ETB receptor-mediated responses (vasodilation, natriuresis) may offer protective effects.
- Development of selective ETA antagonists is warranted; comparative studies of ETA vs. ETA/B antagonists are crucial for disease-specific applications.